The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
A Washington University team solved six cryo-EM structures showing ketamine and PCP bound directly inside the same pocket opioid drugs occupy, not adjacent to it. The finding gives years of behavioral and pharmacological evidence linking ketamine to opioid receptors a direct molecular basis, and it revises a specific claim from the field's own foundational paper on the question.
Fibromyalgia sits entirely outside ketamine's labeled indications, and formulary and prior-authorization decisions for this off-label use have rested on studies of 34 patients or fewer. A new 92-patient retrospective with two years of follow-up is the largest and longest such dataset yet, and it shows both a durable benefit for some patients and a hard ceiling on how many respond at all.
The first peer-reviewed safety and outcomes data from a state-licensed psilocybin program shows strong results: most participants reported benefit, few serious adverse events, and real symptom reductions at three months. The data arrives in the middle of an Oregon Health Authority rulemaking process weighing fee increases that operators say could shut the program down.
A Karolinska Institutet team found that socially dominant mice, not subordinate ones, showed the greater behavioral disruption after chronic stress, and that a single ketamine dose reversed much of it. The result adds a specific, counterintuitive variable to a question this desk keeps circling: why ketamine's antidepressant response varies so much from one patient to the next.
Medical science liaisons engage prescribers on the science, not to sell, and the function takes time to build, which is why companies stand it up well ahead of a launch. Compass has kept a field MSL team for about two and a half years and is now hiring a commercial sales force on top of it, while its COMP360 depression NDA is on track to complete in the fourth quarter of 2026, a commercial-readiness signal that lines up with the company's own approval timeline.
Brenipatide, a Lilly incretin-class compound reported to be a dual GIP/GLP-1 agonist, was positioned for addiction and mood disorders. It is now in Phase 3 for major depression relapse prevention and alcohol use disorder, and in Phase 2 for bipolar disorder, smoking-cessation relapse prevention, opioid use disorder, and schizophrenia. That breadth is the story, not any single trial.
No regulator currently certifies whether an AI chatbot is safe to use for mental health support. NAMI's expanded partnership with digital psychiatry researcher John Torous, and the live MindBench.ai platform it has already produced, is building that evaluation infrastructure directly, ahead of any formal regulatory framework.
Compass Pathways' Redefine Study is a pivotal, FDA-cleared psilocybin trial for PTSD. Resilient's MDMA program is the field's oldest, and it recently resubmitted for approval without new data. The same indication, two companies, two different bets on what regulators will accept.
A theoretical framework built around matrescence and the mother-infant dyad argues the field has waited long enough to study psilocybin in postpartum women. A Johns Hopkins researcher who studies psychedelic adverse events directly names four specific gaps between what the field's leading drug candidate has tested and what a postpartum-specific safety case would require.
Tianeptine produces hippocampal brain activity that an established opioid drug also produces, and that naloxone blocks entirely. Ketamine, tested in the same experiment, does neither. The finding doesn't change tianeptine's regulatory status, but it gives the case for treating it as an opioid-mechanism drug pharmacological evidence to stand on, rather than a proposed threshold and a list of exposure cases alone.
Eli Lilly bought its way into psychedelics at scale. AbbVie did the same for a different compound. Compass built a patent fortress instead of buying one. Resilient, once the furthest ahead of anyone, has reportedly tried again without new data. Read together, the companies leading the pharmaceutical side of this sector are running distinctly different strategies, and the differences say more about who wins than who moved first.
Carey Turnbull built Freedom to Operate specifically to force Compass Pathways to withdraw psilocybin patent claims he considers prior art. His own company, Ceruvia Lifesciences, holds patents on BOL-148, a non-hallucinogenic LSD derivative now advancing into a Phase 1/2 trial for cluster headache. Both things are true, and neither cancels the other out.
HLP003 posts a favorable drug-interaction profile specifically enabling use alongside SSRIs. HLP004 gets patients discharged in three hours instead of eight. Neither result addresses whether these compounds work better than existing psychedelics. Both address the two reasons a clinic or an insurer would hesitate to adopt one at scale.
A University of Michigan team scanned brains under psychedelics, sleep, and propofol sedation and found the same network pattern running in exactly opposite directions. The finding speaks directly to a long-running theoretical debate about the neural basis of consciousness, and points toward one side of it. It also matters for a specific, practical reason: sedation is a common comparator in psychedelic mechanism studies, and this data shows it isn't a neutral baseline.
The real-world-evidence platform behind more than a thousand independent psychiatry practices administering ketamine and esketamine today has signed a multi-year deal to help Tasman Therapeutics design its Phase 3 trial and build its future commercialization infrastructure. Nothing about the deal is improper. It does mark a new kind of player entering psychedelic-adjacent drug development, one whose core asset is neutrality, now becoming financially interested in a single company's outcome.
Voyage's topline GAD data is strong on its own terms, a large effect size in an indication with no new drug since 2007. What makes it worth this desk's attention is what it does alongside two prior positive results, and a companion trial explicitly designed around the same functional-unblinding concerns this desk has tracked across the entire psychedelic drug-development field.
Cancer pain, chronic pelvic pain, phantom limb pain, fibromyalgia, migraine: psilocybin trials are now running across a genuinely wide swath of chronic pain medicine. Nearly all of them share the same structural weakness, a pain-scale endpoint that cannot tell whether the drug changed the pain itself or changed how much the pain bothers the patient. That distinction is the entire story.
Across this desk's coverage this year, CNS and psychiatric trials have repeatedly appeared as completed in registry records while their results remained publicly unavailable. That gap has a name, a legal deadline attached in some cases and none in others, and a compliance record that varies by a factor of five depending on who ran the study. None of it means a trial failed. Almost none of it means nothing.
PIVOT, a new multi-site randomized controlled trial, is the VA's first sponsored efficacy study of psilocybin for treatment-resistant depression in veterans. It launches into an unusually strong proof-of-concept backdrop: an open-label pilot in veterans with severe PTSD, published days earlier, reported no serious adverse events and a 75 percent remission rate.
Executive Order 2026-037 creates a scientific advisory committee to study whether Puerto Rico should build a pilot clinical research program for emerging therapies, including psilocybin, MDMA, and ibogaine, with veterans named as a priority population. The order explicitly does not authorize any clinical use of these compounds, a distinction worth stating plainly before the headline runs ahead of it.
A Phase 2 trial met its endpoint. The FDA granted Breakthrough Therapy status. A drug candidate is moving toward postpartum depression faster than almost anything else in psychiatry right now. Meanwhile, the most rigorous evidence available on what psychedelics actually do to the postpartum body and a nursing infant comes from a single mouse study, and it found something the field's current pace does not yet reckon with.
A retrospective study of 19 patients treated under Switzerland's limited medical-use exemption is among the first real-world psilocybin outcome data generated outside a clinical trial. The response and remission rates land close to what ordinary antidepressants achieve in real-world use, not the dramatic figures the field's early trials reported.
CMS finalized its FY 2027 payment rule for inpatient psychiatric facilities with an in-line-with-inflation rate increase. Buried in the same rule is a new cap on outlier payments, aimed specifically at high-cost facilities, that takes effect a year later and could matter more to some operators than the headline rate does.
Compass's pivotal trials exclude bipolar disorder outright, stated directly in protocol. A trial now recruiting in Houston enrolls bipolar II patients specifically selected for elevated suicide-risk markers, dosed after coming off their mood stabilizers, though it still excludes patients in active crisis. The prior data on this population is thinner and more mixed than the field's caution suggests.
SIMTRIYO's approval gives ADHD its first new mechanism in years, and gives Otsuka a second significant CNS win following its psychedelic-adjacent Transcend acquisition, following a rejection less than a year earlier in a different indication. The approval itself is not the whole story; the drug cannot reach patients until the DEA finishes scheduling it.
A bill to fund the perinatal mental health workforce has sat in committee for over a year while the state's 2024 screening mandate keeps identifying more people who need care. Screening and drug approval both assume a trained clinician exists on the other end. Massachusetts's own numbers say that assumption doesn't hold, and workforce funding deserves the same urgency as everything built on top of it.
A patented, FDA-track product moving through Lilly-scale pharma capital. A licensed-facilitator service model built entirely outside the FDA. A capped state clinical pilot. A federal access program that fixed its supply chain by narrowing who gets through. These are not four routes to the same destination. They are becoming different products, for different patients, at different prices, and the field's habit of discussing psychedelic access as a single question is obscuring that rather than clarifying it.
A targeting trial in TMS, a statistical test built for a tDCS headset, and an autonomic-biomarker study in deep brain stimulation have nothing to do with each other on paper. Read together, they describe the same shift happening in parallel across neuromodulation's major device categories: away from asking whether a device works in aggregate, and toward asking for whom, through what mechanism, and how confidently anyone can tell the difference between a real effect and a confound.
VCU-1012, a laboratory-designed derivative of the little-used psychedelic quipazine, produced antidepressant-like effects in mice without the gastrointestinal side effects of its parent compound. The result is real and mechanistically interesting. It is not evidence of a psychedelic without the trip, and the distinction matters for how the finding should be read.
A retrospective analysis of 3,041 Mindbloom patients reports high rates of clinical improvement from at-home subcutaneous ketamine, a genuinely under-studied delivery route. The topline numbers are real. So is the conflict of interest, the near-total attrition by the final assessment, and the gap between the headline improvement rate and the much lower remission rate underneath it.
The Mystical Experience Questionnaire sits inside nearly every major psychedelic trial as a primary or secondary endpoint. A new review traces its lineage back to a specific, largely unexamined mid-century framework and argues the field inherited a religious category it never should have adopted as science. The proposed fix is more useful than the critique alone: rename the instrument, and use the version its own original architect built later.
CMS's newly proposed physician fee schedule cuts both Medicare conversion factors for 2027, a real, system-wide reimbursement headwind. But the same rule proposes extending Medicare's telehealth mental health flexibility through the end of 2027, and last year's most contested pay cut specifically exempted the time-based codes psychiatry and psychotherapy mostly bill under. The rule is a mixed signal, not a uniform one, and the mix matters more than the headline number.
The $2.8 billion upfront acquisition gives Lilly a late-stage 5-MeO-DMT program and moves psychedelic drug development from speculative biotech into large-pharma pipeline strategy.
Every neuromodulation and psychedelic trial this desk covers eventually runs into the same problem: patients can often tell whether they got the real treatment. A new analysis of a home-use tDCS depression trial does something most studies don't bother with, it empirically tests whether that broken blind actually distorted the outcome, rather than treating unblinding and bias as the same thing.
Final guidance, a public hearing, an interagency MOU, a state pilot program, new federal funding, all inside a matter of weeks. None of it resolves a single one of the open scientific questions this desk has spent the year tracking. Readers, sponsors, and investors who read process speed as scientific validation are making the same mistake the field has made before, with the same likely outcome.
The agreement itself is a coordination document, not a funding commitment or an access pathway. What makes it significant is what it arrived alongside: FDA's final clinical guidance, a September public hearing, and separate ibogaine-specific funding moves from NIDA and ARPA-H, all announced the same day.
Three years after its first draft, FDA has issued final guidance on how to design a psychedelic clinical trial. It does not loosen the bar. It specifies, in granular and sometimes uncomfortable detail, exactly what the agency now expects on blinding, cardiac safety, durability, and drug interactions, the precise questions that have sunk or slowed nearly every program this desk has covered.
The Massachusetts House passed a five-year, three-clinic psilocybin and ibogaine pilot program, tucked into a $561 million economic development bill. Where the state's 2024 legalization ballot measure failed at the polls, this version is narrow, clinical, state-run, and built around a fixed pilot rather than broad personal access, a different model entirely, still needing the Senate and the Governor before it is law.
Psilocybin's clinical trials have repeatedly shown a durable increase in openness after a single supervised dose. A large naturalistic study of German university students set out to see whether that effect shows up in ordinary first-time use. After the statistics were done properly, it mostly disappeared, and what was left wasn't specific to psychedelics at all.
Imperial College London's Centre for Psychedelic Research has published a small, long-running pilot of psilocybin therapy in women with severe, treatment-resistant anorexia nervosa. Eating-disorder symptom scores improved and held for a year in an indication with almost nothing that works. The design, open-label, uncontrolled, in 21 people, sets a hard ceiling on what can be concluded from it.
A federal Schedule I proposal would close the retail loophole that has let tianeptine, an atypical antidepressant abroad and an opioid-like supplement in unregulated US retail, spread through the same gas-station-and-smoke-shop channel as kratom's concentrated derivatives. It is the third distinct DEA scheduling action against this retail category in two weeks.
Compass Pathways' Phase 3 COMP006 trial shows 39 percent of patients on the 25 mg dose maintained response through six months. That number is real. What "maintained" actually means, once you read past the topline, is a post hoc, completers-based analysis in which most patients received an additional intervention along the way. Both things are true at once, and the gap between them is the story.
While psychedelic and cannabinoid drug developers chase headlines, a Texas contract manufacturer has spent the past year and a half filing DEA registration after DEA registration to handle their raw materials, LSD, ibogaine, mescaline, marijuana extract, and more. It is the least glamorous, most necessary layer of the industry, and it is expanding fast.
Canada built two successive federal pathways to get psilocybin and MDMA to patients outside clinical trials. The second one fixed the supply chain the first one lacked, and in doing so made access harder to get, not easier. As U.S. states write their own trigger laws and access frameworks, that trade-off is the one worth studying before it repeats.
DEA and HHS have moved to temporarily schedule concentrated 7-hydroxymitragynine while explicitly leaving natural kratom leaf alone, using a numeric potency threshold instead of a categorical ban. Where that threshold finally lands, and how it is measured, will determine how much of the existing kratom market ends up scheduled; the public comment window on it closed July 31.
A Copenhagen research program is mapping the direct dose-occupancy relationship between LSD and the serotonin 2A receptor in living human brains, the pharmacodynamic binding data that clinical psychedelic trials have mostly assumed rather than measured. With interim results already published and the full program running through 2027, it is the empirical foundation the dosing decisions in Definium's lysergide program could stand to be built on.
Researchers have systematically catalogued clinics using direct-to-consumer advertising to sell off-label ketamine in the New York metro area, the densest such market yet studied. A comparable study elsewhere found extensive misrepresentation of the drug's approval status and risks. The empirical baseline now exists. What regulators do with it is the open question.
Compass Pathways' crystalline-polymorph psilocybin patent has reached granted status as COMP360 moves into rolling FDA submission and the regulatory path clears. Psilocybin itself cannot be patented, so the entire pharmaceutical-psilocybin model rests on owning the exact crystalline form, and patent lawyers still disagree on how much that actually blocks.
The Defense Department's adaptive platform trial, the efficient vehicle built to test the next generation of PTSD drugs after the MDMA rejection, has been suspended, master protocol and every arm. The registration explains it only as deferred. PTSD pharmacology, stuck on two-decade-old antidepressants, is left waiting again.
Psilocybin for smoking cessation produced some of the most striking pilot results in psychedelic medicine, up to 80 percent abstinence in the first tiny study. It is now in a NIDA-funded multi-site Phase 2, which is both a marker of federal money entering psychedelic-addiction research and the test of whether those eye-popping early effects survive rigor.
SAMHSA has opened a comment period on building an independent accreditation system for the federal Certified Community Behavioral Health Clinic expansion program, a 500-clinic, now-permanent Medicaid benefit. The design choices being written now, who accredits, what the standards are, and whether failing costs grant money, will set the operating economics for a large slice of the behavioral-health-services sector.
A new multi-site trial puts tirzepatide, the metabolic GLP-1/GIP agonist, into moderate-to-severe cannabis use disorder, an indication with no approved medication. It extends an increasingly addiction-wide bet on a single reward mechanism, and for the cannabis market the same drug class is both a demand threat and a possible cure.
A multicentre trial reported that a single dose of esketamine around childbirth helps prevent postpartum depression. It arrived with a formal comment and author reply in the same issue, and the dispute lands on exactly the two problems the desk keeps flagging: a blind the drug's own side effects may have broken, and a benefit braided into pain relief.
A new West Virginia statute is being read as a state prescription pathway for psilocybin that runs ahead of federal scheduling. It is the opposite: a contingent trigger that activates only if the FDA approves and the DEA reschedules a crystalline-polymorph psilocybin first. That structure, and the polymorph language, quietly pick a side in how psilocybin access gets built.
A new review finds that at the doses used for mood disorders, ketamine mostly causes mild, transient liver enzyme bumps, with serious hepatotoxicity rare. The catch is in the fine print: the dangerous cases cluster at high cumulative exposure, which is exactly the direction expansion, maintenance dosing, and the off-label clinic boom are pushing toward.
A JAMA Psychiatry randomized trial found that aiming accelerated TMS with individual brain imaging beat the standard scalp-landmark method, an 80 percent response rate against 60. It is the strongest evidence yet that the personalized approach earns its cost, which pushes the fastest-growing depression neuromodulation toward precision, expense, and the imaging-capable centers that can deliver it.
Brenipatide, Lilly's CNS-optimized dual GIP/GLP-1 agonist, is now in trials across depression, bipolar disorder, alcohol use disorder, smoking, and schizophrenia. The new bipolar Phase 2 is one tile in a portfolio that answers a question this desk raised: whether the owner of the era's most valuable drug class would bring it into psychiatry. It would, comprehensively.
The commercial hope in psychedelics is a drug that keeps the antidepressant effect and drops the hallucination by being selective for the 5-HT2A receptor. The preclinical evidence points the other way: psilocybin's benefit appears to depend on more than 5-HT2A, and if the missing piece is a receptor like 5-HT2B, the one developers normally design around for cardiac safety, two of the field's bets get harder at once.
Definium Therapeutics, the company formerly known as MindMed, reported positive topline Phase 3 results for an orally dissolving form of LSD in major depression. With a second MDD trial, two Phase 3 anxiety trials, and a PTSD study to come, lysergide is now arguably the most advanced classic psychedelic in registrational development. The trial design takes direct aim at the field's biggest methodological problem.
MDMA-assisted therapy is moving beyond PTSD into eating disorders, on the logic that trauma underlies many of these conditions. It is a real research direction, but not a first, and the evidence so far is a secondary analysis and a few early trials. That is the right place to set expectations.
Psilocybin's strongest cancer evidence is in anxiety and depression. A Roswell Park trial extends it to chronic cancer pain and opioid reduction, part of a broader psychedelics-for-pain wave. Treating pain is a different and less-supported claim than treating distress, and the distinction is the whole story.
A target trial emulation examines esketamine in patients with cancer-related depression, with a survival endpoint. It is a genuinely new population for the drug. It is also a single observational cohort measuring the most confounded outcome there is, which is exactly why the result, whatever it shows, has to be read with discipline.
OCD is not depression. Different circuitry, possibly a different mechanism. A systematic review of ketamine in OCD marks the field taking the question seriously, but it synthesizes a small, preliminary literature. The real test is whether ketamine's effect holds up in a disorder built differently, and in the patients who most need it.
NIAAA opened Phase 1 trials of tirzepatide and suvorexant for alcohol use disorder in the same cycle, both probing the brain's reward circuitry. It is the addiction version of a pattern the desk keeps seeing, a neglected indication revived by federal repurposing of approved drugs. With one difference that matters commercially.
MDMA cannot be patented; it is a 1912 molecule. So the commercial action has moved to engineered analogues, especially short-acting ones that would shrink the eight-hour session that makes MDMA therapy hard to scale. After the 2024 FDA rejection, the filings, not the trials, are where the next MDMA strategy is taking shape.
Vagus nerve stimulation, deep brain stimulation, and now non-invasive temporal interference form a device-based axis of behavioral health that gets covered one gadget at a time, never as a category. Seen whole, it shares a single obstacle: proving itself against a sham.
On the same day, the New England Journal of Medicine ran one piece on the collision between state-authorized psychedelic programs and federal Schedule I status, and another on informed consent and shared decision-making in psychedelic care. The pairing, and the venue, are the signal: the field's unresolved questions are now jurisdictional and ethical, not pharmacological.
Obsessive-compulsive disorder still runs on SSRIs and clomipramine, the latter from the 1960s. A cluster of academic trials is testing repurposed drugs with mechanisms outside the serotonin paradigm. It is a research-interest revival, not a commercial pipeline, and the distinction is the story.
A Yale Phase 1 is testing DMT in major depression with EEG endpoints, part of a psychedelic quietly catching up to psilocybin and MDMA. Its short duration is the structural answer to the session-length problem the rest of the field is spending money to engineer. Whether brevity is enough is the open question.
A new paper quantifies MDMA's concentration-dependent inhibition of CYP2D6, the enzyme that metabolizes several antidepressants common in the PTSD population MDMA therapy is meant to treat. The pharmacokinetic interaction is real, though it is not the only reason concomitant antidepressants get managed.
The medical-cannabis expansion is the headline. The same day, separate bills reconstitute the state's community service boards, tighten facility staffing and workforce-data requirements, and add reporting duties for cannabis-certifying physicians. The plumbing changes will outlast the headline.
A CMS proposed rule published June 16 would codify the negotiation program, scale it toward 20 drugs a year, and make it harder to challenge. Vraylar is set for a 44 percent Medicare price cut in 2027. Psychiatric pharma is now inside the regime, and the exposure only grows from here.
A federally funded Phase 2 will test hydroxynorketamine, the ketamine metabolite hypothesized to deliver the antidepressant effect without the dissociation or abuse risk. The idea has been contested for a decade, and the human data so far is not encouraging. The result bears on every clean-ketamine program in the pipeline.
In a single cycle, ketamine programs advanced in bipolar depression, anorexia, and postpartum depression, on top of the oral and deuterated reformulations already in the clinic. The breadth is real, and it says more about the economics of an off-patent molecule than about new biology.
Compass's pivotal evidence spans North America and Europe and points toward an FDA filing. Australia skipped that route in 2023, letting psychiatrists prescribe psilocybin with no completed pivotal trial. The global path to psychedelic access is fragmenting into models that do not agree on what evidence is required first.
Federal money for psychedelics went from nothing to a real portfolio in two years. It is not a copy of the company pipeline. The NIH is funding the questions private capital has structural reasons to skip.
Transcend's methylone is in Phase 3 for PTSD, holds FDA Breakthrough and priority-voucher status, and just drew a $1.2 billion acquisition from Otsuka. Its pitch is that it delivers the benefit of MDMA without the hallucinogenic experience that helped sink the MDMA application.
Deuteration replaces a hydrogen atom with its heavier isotope to slow a specific step of metabolism. It is a precision pharmacokinetic tool, not a new mechanism, and it has become a favored way to re-engineer known psychiatric molecules. Here is what it does, what it has already done, and what it cannot do.
Bristol Myers is running a separate Phase 3 program, ADAGIO, for agitation in Alzheimer's, distinct from its psychosis trials. Agitation already has an approved treatment. So this is a challenge on safety, not a first move, and the data is years away.
HLP003, Helus Pharma's deuterated psilocin analog engineered for a shorter trip, is now months from its first Phase 3 readout in major depression. It does not differ from Compass on biology. It differs on session length, dosing, and the breadth of the population it targets.
A new multicentre trial adds to a decade of randomized studies testing the ketamine class against postpartum depression. They keep producing the same result: a real short-term signal on a screening scale, in a setting that confounds it, that fades before it counts.
ACADIA's deuterated ketamine metabolite, Helus Pharma's deuterated psilocin, and the entire esketamine franchise are the same move: take a known psychoactive molecule and re-engineer its pharmacokinetics. The mechanism stopped being the contest. Deployability is.
ACP-211 is a deuterated form of R-norketamine that ACADIA is testing as a standalone pill in treatment-resistant depression. The framing is a direct contrast with Spravato. The mechanism carries the same questions that follow every ketamine-class drug.
A new PNAS paper reports that psychedelics scramble hierarchical cortical propagation in the default mode network across both humans and mice. The cross-species match strengthens the case that this disruption is a real circuit mechanism. It says nothing yet about whether the disruption helps anyone.
The Oversight of Artificial Intelligence Technology in Mental Health Care Act, H7349, was signed on June 22, 2026, after clearing the House in substitute form. Rhode Island is among the first states to govern clinical AI in mental health rather than ban it, and the enacted text now sets the scope and enforcement.
The closest analog to a psychedelic approval is the one that already happened. Spravato took six years to reach $1 billion in annual revenue and is now Johnson & Johnson's fastest-growing neuroscience product. The launch curve has lessons for every program waiting on the voucher review window.
On September 4, 2025, the FDA released the redacted Complete Response Letter to Lykos as part of a broader publication of 89 previously unpublished CRLs. The document is now public reading. The methodological concerns it documents are more specific than the press coverage suggested, and the implications for the field's subsequent programs are larger.
SB 220 took effect July 1, replacing the 5 percent THC cap, legalizing vaporization, and adding conditions. It is the biggest cannabis-policy shift since the program launched, and PTSD keeps it tied directly to the mental health debate.
A cluster of papers in the June American Journal of Psychiatry adds evidence that ketamine's antidepressant and antisuicidal effects engage the mu-opioid receptor. That undercuts the clean-glutamate story the approved franchise was built on, and revives the abuse-liability question the field has tried to set aside.
One law governs AI used in clinical treatment. Another sets safety rules for companion chatbots. Signed together on June 22, 2026, they form a govern-it model other states are watching as the alternative to an outright ban.
A decade of breakthroughs, advisory committee meetings, draft guidance documents, and one rejection. The agency's position has been consistent in ways the field has been slow to acknowledge, and the current voucher moment makes more sense read against the full record than against any individual moment.
A five-year NIDA award sends federal researchers into Oregon's legal psilocybin program to track safety and substance-use outcomes in thousands of real clients. It is the first dataset built from psychedelic use outside controlled-trial conditions, and that is the point.
Most of the recent antidepressant approvals are reformulations, recombinations, or rediscoveries of mechanisms the field had previously left behind. The volume of actually new pharmacology is much narrower than the press coverage suggests, and the structural reasons matter for sponsors planning the next wave.
CMS's January 2025 creation of three Medicare reimbursement codes for digital mental health treatment is the most consequential thing that has happened to the prescription digital therapeutics market since the FDA started clearing them. The codes' narrow scope is doing more to shape the field than the clearances themselves.
Compass hit both pivotal trials, has a rolling NDA underway, and holds a priority voucher that could compress review to one or two months. The regulatory path is now the fast part. The durability and effect-size data are the part still being written.
The Justice Department already rescheduled medical cannabis. The June 29 to July 15 hearing considered whether the rest of the market follows, and closed without a ruling. A guide to the parties, the question before the judge, the timeline, and what each outcome does to operators.
Hims and Hers, the category's public bellwether, grew 4 percent last quarter and swung to a loss. The growth now comes from branded weight-loss drugs and overseas expansion. Mental health is one specialty on a platform that has stopped being about mental health.
A new antipsychotic mechanism reached the market as a monotherapy. Its adjunctive trial missed, the rival M4 drug failed outright, and the Alzheimer's readout slipped a year on data irregularities. The mechanism is real. Every bet built on top of it is still unproven.
A map of the surviving programs after the August 2024 MDMA rejection and the April 2026 voucher decisions. The field is narrower than press coverage suggests, and the survivors are concentrated in a small number of well-funded sponsors with overlapping bets on the same handful of molecules.
The single most consequential line item in any cannabis operator's tax return is the disallowance under Section 280E. The April 2026 DOJ order does not eliminate it. It bifurcates it. The mechanics matter, and they are routinely misreported.
The two concepts are routinely conflated, and the conflation has cost the field a decade. Why blinding fails in psychedelic trials, why expectancy is a separate and harder problem, and what trial designs actually solve for it.
Five FDA acceleration programs get conflated in coverage. They do different things, require different evidence, and create different post-approval obligations. A reference for telling them apart.
Psilocybin cleared two Phase 3 trials, cannabis moved partway to Schedule III, a new antipsychotic mechanism reached market, and telehealth kept scaling. In each vertical, the mechanism is narrower than the coverage.
The voucher list does the talking. The same FDA that issued the Lykos CRL still issued the vouchers, and it sent them to programs whose methods it considers defensible. Sponsors who hear political acceleration as scientific accommodation will misread it as the field misread the original draft guidance, and pay the same kind of price.
Six days after Trump's executive order, the agency named three programs for one-to-two-month reviews. The picks reset the field's near-term hierarchy and confirm the methodological reasons the MDMA program is still on the outside.
An evergreen reference on what actually matters in a psychedelic-assisted therapy trial readout: blinding analyses, expectancy controls, dose-response designs, and the questions to ask before you trust the headline number.
Most coverage of rescheduling fixates on 280E tax relief. The bigger story is what happens to research registration, FDA pathway access, and the M&A market for MSOs that have been frozen out of institutional capital for a decade.
When the FDA approved zuranolone for postpartum depression but rejected it for major depressive disorder, it built a commercial trap Sage could not escape independently. Supernus completed its acquisition of the company on July 31, 2025. The lesson about narrow psychiatric labels generalizes regardless.
Direct-to-consumer mental health platforms built businesses on the difference between cash-pay convenience and insurance reimbursement complexity. That gap is closing, not because of a regulatory clampdown that never happened, but because of the reimbursement side alone, and because the insurance-credentialed marketplaces that were supposed to be the beneficiaries are consolidating and straining under the same payer pressure.